An intranasal vaccine candidate (BBV154), being developed by Bharat Biotech, is in early clinical stage of development in India, Minister of State for Health Ashwini Choubey told the Rajya Sabha on Tuesday.
Mr Choubey was responding to a question on the status of launching a nasal vaccine for COVID-19.
Most vaccines are administered by injection through intramuscular or subcutaneous route. But, intranasal vaccines are administered as a nasal spray and offer a needle-free approach for vaccine administration, Mr Choubey said in a written reply.
"The interval period between the two doses is presently 21 days. The schedule will be finalized after the phase I clinical trial data. Currently, in phase I clinical trial, single dose and two dose schedules are being tested," the minister said.
BJP Leader Says Party Should Contest Bihar Assembly Polls On Its Own Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent Covid Vaccinated Pregnant Women At Lower Risk Of Caesarean Births: Study Israeli Jets Strike Yemen Rebels After Deadly Attack On Tel Aviv Woman On Scooter With 2 Kids Punched, Left Bleeding In Pune Road Rage Case After Retest, Haryana NEET Centre With Most Top Scorers Gave This Result... CrowdStrike Bug hit 8.5 Million Windows Devices, Says Microsoft Imran Khan Being Kept In Filthy Circumstances In Jail, Says His Wife: Report 7 Bombs Defused In Imphal East District By Joint Army, Police Team Track Latest News Live on NDTV.com and get news updates from India and around the world.